<DOC>
	<DOC>NCT02314442</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-PCSSC in subjects with elevated LDL-C.</brief_summary>
	<brief_title>A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Adequate complete blood counts, liver and renal function Female subjects must be of nonchildbearing potential; e.g. postmenopausal or premenopausal with surgical sterilization Male subjects agree to use appropriate contraception Willing to provide written informed consent and willing to comply with study requirements. Nonsmokers and nonnicotine users for at least 90 days before screening On stable statin comedication [for designated multiple dose cohorts only] Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical study and/or put the subject at significant risk Received an investigational agent within 90 days before the first dose of study drug or are in followup of another clinical study History of multiple drug allergies or intolerance to subcutaneous injection Received any medication or nutraceutical to alter serum lipids within 30 days before screening (nonstatin cohorts only)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>LDL-C</keyword>
	<keyword>RNAi therapeutic</keyword>
</DOC>